Viking Therapeutics (VKTX) Posts Q2 Loss of $1.07/Share

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 11/4/2026

1. AMD
2. BKNG
3. AMGN
4. DOX
5. DUOL
6. ANET
7. SWKS
8. XYZ
9. SPY
10. FISV

Go back to Viking Therapeutics (VKTX) Posts Q2 Loss of $1.07/Share

Viking Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update

August 13, 2015 7:44 AM EDT

Phase 2 Clinical Studies to Begin in Acute Hip Fracture and Hypercholesterolemia/Fatty Liver Disease

Completes $22.3 Million IPO

SAN DIEGO, Aug. 13, 2015 (GLOBE NEWSWIRE) -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel, first-in-class or best-in-class therapies for metabolic and endocrine disorders, today announced financial results for the second quarter of 2015 and provided an update on its clinical pipeline and other corporate developments.

Highlights From, and Subsequent to, the Three Months Ended June 30, 2015

"We made... More